Kallyope Website, Blog & Press Pages

Kallyope Website, Blog & Press Pages - aVenture

Kallyope - Library

trigemxbio.comCrawled Oct 15, 2026

Product

5 pages

Platform/platform
The Klarity Platform uses integrated technologies to provide insights into neural circuits involved in migraine and metabolism.
Elismetrep Archives/program/elismetrep
Integrated End-to-End Technologies/platform
The Klarity Platform uses integrated technologies to provide insights into neural circuits involved in migraine and metabolism.
Novel Therapies/pipeline
The company is developing programs targeting neural circuits for migraine treatment.

Press

7 pages

News/news
View the latest news about advances at Kallyope.
Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine/kallyope-announces-positive-results-from-phase-2b-study-of-elismetrep-for-the-acute-treatment-of-migraine
Novel mechanism of TRPM8 antagonism may offer new option for large number of patients suffering from debilitating migraines Full data to be presented at a
Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting/kallyope-presents-new-data-on-novel-trpm8-channel-blocker-elismetrep-for-the-acute-treatment-for-migraine-at-the-american-headache-society-68th-annual-scientific-meeting
Results contribute to growing body of evidence in support of elismetrep, a TRPM8 migraine-associated channel blocker (MACB), to help address the
Kallyope to Present Phase 2b Study Results for Elismetrep for the Acute Treatment of Migraine at the 2026 American Academy of Neurology Annual Meeting/kallyope-to-present-phase-2b-study-results-for-elismetrep-for-the-acute-treatment-of-migraine-at-the-2026-american-academy-of-neurology-annual-meeting
Clinically meaningful data establishes proof of concept for elismetrep as a promising therapeutic candidate for migraine and its progression into

Careers & Hiring

2 pages

Careers/careers
Kallyope is a clinical-stage biotech founded and located in NYC.
Careers/careers
TriGemX was founded and is located in NYC.

About

2 pages

About/about
The company aims to discover and develop agents for neurological and metabolic diseases that are effective, easy to use, and well tolerated.
About us/about
The company is developing an agent for migraine patients.

Contact

2 pages

Contact/contact
The company provides a contact form for messages.
Contact us/contact

Homepage

2 pages

Homepage/
Kallyope develops medicines for migraine and metabolic disorders based on insights into neural signaling pathways.
Homepage/
TriGemX Bio is developing medicines for migraine treatment based on insights into neural signaling pathways.

Coverage

5 items

Kallyope Announces 2026 Strategic Priorities for Migraine and Metabolism Portfolio Based on Novel Neural Circuits Platformkallyope.com/kallyope-announces-2026-strategic-priorities-for-migraine-and-metabolism-portfolio-based-on-novel-neural-circuits-platform/
Kallyope outlines its 2026 strategic priorities for its migraine and metabolism portfolio, built on its neural circuits platform. The portfolio includes elismetrep and K-554.
Jan 2026 · KallyopeNews article
Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migrainekallyope.com/kallyope-announces-positive-results-from-phase-2b-study-of-elismetrep-for-the-acute-treatment-of-migraine/
Kallyope reports positive results from a Phase 2b study of elismetrep for acute migraine treatment. Elismetrep is an oral, selective TRPM8 channel blocker.
Dec 2025 · KallyopeNews article
Investors Go With Their Gut, Dropping 236M Into Kallyopebiospace.com/investors-go-with-their-gut-dropping-236m-into-kallyope
Kallyope raises a $236 million Series D financing round to advance its gut-brain axis programs. The announcement provides the round size and broad research focus but does not name participating investors or describe individual programs, development plans, or specific milestones.
Feb 2022 · BioSpaceNews article
Kallyope Advances Gut-Brain Axis Treatment With New Financingpharmaceutical-technology.com/news/kallyope-gut-brain-axis-treatment/
Kallyope advances its gut-brain axis treatment programs following a Series D financing. The report gives no financing amount or further details about the treatment programs.
Feb 2022 · Pharmaceutical TechnologyNews article